Health Care [ 9/12 ] | Health Care Equipment & Supplies [ 56/74 ]
NASDAQ | Common Stock
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices for use in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets.
Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as process fingerprint data to support large-scale efforts in predictive bioprocess modeling.
The company's products comprise Maven, an on-line device for bioprocess monitoring and control; Trace C2, an on-line monitoring of methanol or ethanol and control of substrate feeding in fermentation processes; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis.
It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas.
The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 3, 25 | -0.28 Decreased by -21.87% | -0.35 Increased by +19.15% |
| Nov 12, 24 | -0.84 Decreased by -284.09% | -0.28 Decreased by -201.79% |
| Aug 6, 24 | -0.31 Decreased by -6.90% | -0.33 Increased by +6.06% |
| Apr 30, 24 | -0.33 Increased by +15.38% | -0.36 Increased by +8.33% |
| Mar 5, 24 | -0.23 Increased by +25.81% | -0.26 Increased by +11.54% |
| Nov 7, 23 | -0.22 Decreased by -10.00% | -0.30 Increased by +26.67% |
| Aug 8, 23 | -0.29 Decreased by -11.54% | -0.35 Increased by +17.14% |
| May 9, 23 | -0.39 Decreased by -30.00% | -0.35 Decreased by -11.43% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 18.82 M Increased by +31.14% | -19.45 M Decreased by -161.76% | Decreased by -103.33% Decreased by -99.60% |
| Sep 30, 24 | 16.77 M Increased by +17.32% | -29.30 M Decreased by -313.01% | Decreased by -174.66% Decreased by -252.04% |
| Jun 30, 24 | 14.05 M Increased by +16.15% | -12.55 M Decreased by -34.26% | Decreased by -89.33% Decreased by -15.59% |
| Mar 31, 24 | 9.99 M Increased by +5.31% | -10.92 M Decreased by -0.51% | Decreased by -109.27% Increased by +4.56% |
| Dec 31, 23 | 14.35 M Increased by +23.26% | -7.43 M Increased by +19.63% | Decreased by -51.77% Increased by +34.80% |
| Sep 30, 23 | 14.30 M Decreased by -9.50% | -7.09 M Decreased by -32.23% | Decreased by -49.61% Decreased by -46.11% |
| Jun 30, 23 | 12.09 M Increased by +8.90% | -9.35 M Decreased by -15.40% | Decreased by -77.28% Decreased by -5.97% |
| Mar 31, 23 | 9.49 M Increased by +14.22% | -10.86 M Decreased by -16.68% | Decreased by -114.49% Decreased by -2.16% |